ML-007 explained

ML-007 is a selective muscarinic acetylcholine M₁ and M₄ receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias.^{[1] [2] [3] [4]} It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC). The drug is taken by mouth.

As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias. It is under development by MapLight Therapeutics. The drug is a small molecule, but its chemical structure does not seem to have been disclosed.

See also

• Emraclidine
• NBI-1117568
• NS-136
• Xanomeline/trospium

Notes and References

1. Web site: ML 007 . AdisInsight . Springer Nature Switzerland AG . 9 January 2024 . 21 October 2024.
2. Web site: Delving into the Latest Updates on ML-007 with Synapse . Synapse . 19 September 2024 . 21 October 2024.
3. Yohn SE, Harvey PD, Brannan SK, Horan WP . The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia . Frontiers in Psychiatry . Frontiers Media SA . 15 . 4 October 2024 . 1664-0640 . 10.3389/fpsyt.2024.1421554 . free . 11525114 .
4. Walker LC, Huckstep KL, Becker HC, Langmead CJ, Lawrence AJ . Targeting muscarinic receptors for the treatment of alcohol use disorders: Opportunities and hurdles for clinical development . British Journal of Pharmacology . 181 . 22 . 4385–4398 . November 2024 . 37005377 . 10.1111/bph.16081 . free .